Table 1.
Clinicopathologic characteristics of the GDPH TNBC cohort (N=89).
| Variables | TNBC | No-special Type | Special Type | p | |||
|---|---|---|---|---|---|---|---|
| N=89 | No. (%) | N=72 | No. (%) | N=17 | No. (%) | ||
| Age | 0.813 | ||||||
| [median, range] | 49 | [22-81] | 49 | [23-75] | 46 | [22-81] | |
| ≤50 years | 52 | 58.4 | 43 | 59.7 | 9 | 52.9 | |
| >50 years | 37 | 41.6 | 29 | 40.3 | 8 | 47.1 | |
| Menopausal status | 1 | ||||||
| Pre-menopause | 49 | 55.1 | 40 | 55.6 | 9 | 52.9 | |
| Post-menopause | 40 | 44.9 | 32 | 44.4 | 8 | 47.1 | |
| T-stage | 0.428 | ||||||
| T1 | 39 | 43.8 | 33 | 45.8 | 6 | 35.3 | |
| T2 | 40 | 44.9 | 30 | 41.7 | 10 | 58.8 | |
| T3 | 6 | 6.7 | 6 | 8.3 | 0 | 0.0 | |
| T4 | 4 | 4.5 | 3 | 4.2 | 1 | 5.9 | |
| N-stage | 0.604 | ||||||
| N0 | 48 | 53.9 | 39 | 54.2 | 9 | 52.9 | |
| N1 | 22 | 24.7 | 16 | 22.2 | 6 | 35.3 | |
| N2 | 13 | 14.6 | 11 | 15.3 | 2 | 11.8 | |
| N3 | 6 | 6.7 | 6 | 8.3 | 0 | 0.0 | |
| M-stage | 1 | ||||||
| M0 | 88 | 98.9 | 71 | 98.6 | 17 | 100.0 | |
| M1 | 1 | 1.1 | 1 | 1.4 | 0 | 1.0 | |
| Pathologic stage | 0.621 | ||||||
| I | 27 | 30.3 | 22 | 30.6 | 5 | 29.4 | |
| II | 42 | 47.2 | 32 | 44.4 | 10 | 58.8 | |
| III | 19 | 21.3 | 17 | 23.6 | 2 | 11.8 | |
| IV | 1 | 1.1 | 1 | 1.4 | 0 | 0.0 | |
| Histologic grade | 0.022# | ||||||
| I | 1 | 1.1 | 1 | 1.4 | 0 | 0.0 | |
| II | 17 | 19.1 | 12 | 16.7 | 5 | 29.4 | |
| III | 69 | 77.5 | 59 | 81.9 | 10 | 58.8 | |
| NA | 2 | 2.2 | 0 | 0.0 | 2 | 11.8 | |
| Ki-67(%) | 0.040# | ||||||
| [median, range] | 65 | [5-95] | 70 | [10-95] | 50 | [5-90] | |
| <14% | 7 | 7.9 | 3 | 4.2 | 4 | 23.5 | |
| ≥14% | 81 | 91.0 | 68 | 94.4 | 13 | 76.5 | |
| <30% | 18 | 20.2 | 11 | 15.3 | 7 | 41.2 | 0.048# |
| ≥30% | 70 | 78.7 | 60 | 83.3 | 10 | 58.8 | |
| NA | 1 | 1.1 | 1 | 1.4 | 0 | 0.0 | |
| AR | 0.002# | ||||||
| Positive (≥1%) | 16 | 18.0 | 8 | 11.1 | 8 | 47.1 | |
| Negative (<1%) | 59 | 66.3 | 50 | 69.4 | 9 | 52.9 | |
| NA | 14 | 15.7 | 14 | 19.4 | 0 | 0.0 | |
| TILs | 0.092 | ||||||
| Low (0-10%) | 36 | 40.4 | 27 | 37.5 | 9 | 52.9 | |
| Intermediate (10-40%) | 14 | 15.7 | 14 | 21.5 | 0 | 0.0 | |
| High (40-90%) | 32 | 36.0 | 24 | 33.3 | 8 | 47.1 | |
| NA | 7 | 7.9 | 7 | 9.7 | 0 | 0 | |
| Histologic type | <0.001# | ||||||
| IDC | 72 | 81.0 | 72 | 100.0 | 0 | 0.0 | |
| Mixed | 6 | 6.7 | 0 | 0.0 | 6 | 35.3 | |
| AC | 5 | 5.6 | 0 | 0.0 | 5 | 29.4 | |
| MC | 4 | 4.5 | 0 | 0.0 | 4 | 23.5 | |
| MBC | 1 | 1.1 | 0 | 0.0 | 1 | 5.9 | |
| GRCC | 1 | 1.1 | 0 | 0.0 | 1 | 5.9 | |
The p-value was calculated using the Pearson χ2 test and Fisher’s exact test; #, p-value<0.05. TNBC, triple-negative breast cancer; TILs, tumor-infiltrating lymphocyte; AR, androgen receptor; IDC, infiltrating ductal carcinoma; Mixed, mixed histologic; AC, apocrine Carcinoma; MC, medullary carcinoma; MBC, metaplastic breast carcinoma.